# Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants

> **NCT00001830** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 110 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Graft vs Host Disease
- Hodgkin's Disease
- Multiple Myeloma
- Non Hodgkin's Lymphoma

## Interventions

- **DRUG:** Th2 cells in allo HSCTT
- **DRUG:** Th2 Cells

## Key facts

- **NCT ID:** NCT00001830
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-07-20
- **Primary completion:** —
- **Final completion:** 2015-05-19
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2018-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001830, "Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00001830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*